Sartorius (FRA:SRT3) received a €101.00 ($117.44) price objective from research analysts at Commerzbank in a report released on Friday. The brokerage currently has a “sell” rating on the stock. Commerzbank’s price objective points to a potential downside of 17.35% from the company’s previous close.
Several other research firms have also recently weighed in on SRT3. HSBC set a €99.00 ($115.12) price objective on shares of Sartorius and gave the company a “sell” rating in a report on Thursday. Berenberg Bank set a €110.00 ($127.91) price objective on shares of Sartorius and gave the company a “neutral” rating in a report on Thursday. Four research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of €93.60 ($108.84).
Shares of SRT3 traded down €3.40 ($3.95) during mid-day trading on Friday, hitting €122.20 ($142.09). 113,032 shares of the company traded hands. Sartorius has a 1 year low of €71.00 ($82.56) and a 1 year high of €124.70 ($145.00).
Sartorius Company Profile
Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Featured Story: Earnings Per Share (EPS) Explained
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.